PDX Portal

Model Details

Patient Information for Model: BCM-2665

Model Contact

Model: BCM-2665
Model Contact: Michael Lewis
Institution: BCM Breast PDX Program
Email: mtlewis@bcm.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: BCM-2665

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

GeneFilter by Gene	ChrFilter by Chr	Start	End	Ref	Alt	cDNA Change	Codon Change	Protein Change	TVAF	Gene Mutation Freq.	Site Mutation Freq.	Most Severe Effect	All Effects	Mutation Impact	Transcript ID	COSMIC ID	dbSNP ID	Gene Mutation Freq.	Site Mutation Freq.	Transcript ID	COSMIC ID	dbSNP ID
A1CF	chr10	50806745	50806745	C	A	c.1745G>T	gGa/gTa	p.G582V	0.071	20	1	Missense Variant	Missense Variant	MODERATE	ENST00000373997.8		.	20	1	ENST00000373997.8		.
ABI1	chr10	26860781	26860781	C	A	c.83G>T	cGg/cTg	p.R28L	0.02	5	1	Missense Variant	Missense Variant	MODERATE	ENST00000376142.6		.	5	1	ENST00000376142.6		.
ABL1	chr9	130854977	130854977	G	T	c.430G>T	Ggg/Tgg	p.G144W	0.043	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6		.	55	1	ENST00000318560.6		.
ABL1	chr9	130885592	130885592	C	A	c.3302C>A	cCg/cAg	p.P1101Q	0.039	55	2	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6	COSV100583563	.	55	2	ENST00000318560.6	COSV100583563	.
ABL1	chr9	130885352	130885352	G	T	c.3062G>T	cGg/cTg	p.R1021L	0.033	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6	COSV100584237	.	55	1	ENST00000318560.6	COSV100584237	.
ABL1	chr9	130885301	130885301	C	A	c.3011C>A	cCt/cAt	p.P1004H	0.034	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6		.	55	1	ENST00000318560.6		.
ABL1	chr9	130884503	130884503	G	T	c.2213G>T	cGg/cTg	p.R738L	0.094	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6		.	55	1	ENST00000318560.6		.
ABL1	chr9	130884488	130884488	C	A	c.2198C>A	tCa/tAa	p.S733*	0.086	55	1	Nonsense Mutation	Nonsense Mutation	HIGH	ENST00000318560.6		.	55	1	ENST00000318560.6		.
ABL1	chr9	130878459	130878459	C	A	c.1315C>A	Cct/Act	p.P439T	0.082	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6		.	55	1	ENST00000318560.6		.
ABL1	chr9	130878433	130878433	G	T	c.1289G>T	tGg/tTg	p.W430L	0.091	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6	COSV100583417	.	55	1	ENST00000318560.6	COSV100583417	.
ABL1	chr9	130872913	130872913	G	T	c.961G>T	Ggg/Tgg	p.G321W	0.088	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6	COSV59331786	.	55	1	ENST00000318560.6	COSV59331786	.
ABL1	chr9	130855056	130855056	G	T	c.509G>T	aGg/aTg	p.R170M	0.095	55	1	Missense Variant	Missense Variant	MODERATE	ENST00000318560.6		.	55	1	ENST00000318560.6		.
ABL2	chr1	179107776	179107776	G	T	c.3491C>A	cCt/cAt	p.P1164H	0.027	11	1	Missense Variant	Missense Variant	MODERATE	ENST00000502732.6		.	11	1	ENST00000502732.6		.
ABL2	chr1	179121663	179121663	G	T	c.892C>A	Cag/Aag	p.Q298K	0.025	11	1	Missense Variant	Missense Variant	MODERATE	ENST00000502732.6		.	11	1	ENST00000502732.6		.
ABL2	chr1	179121656	179121656	C	A	c.899G>T	gGa/gTa	p.G300V	0.015	11	1	Missense Variant	Missense Variant	MODERATE	ENST00000502732.6	COSV61015032	.	11	1	ENST00000502732.6	COSV61015032	.

CNV

PDX Validation

In order to validate the identity of Baylor College of Medicine patient-derived xenograft (PDX) models, short tandem repeat (STR) testing is performed at the Cytogenetics and Cell Authentication core facility at MDACC. STR testing is performed on tissue from the initial tumor grown in the mouse (transplant generation 1 - TG1) and from a patient sample when possible. Thereafter, STR testing is performed every five transplant generations (TG5, TG10, TG15, and TG20). In the case that a PDX model is transplanted from viably frozen tissue to restart the model, the PDX Core will test the first outgrowth to confirm identity and every five transplant generations thereafter. In addition to STR, we assess clinical biomarkers and histology every 5th transplant generation. Finally, RNAseq gene expression profiles are evaluated periodically to ensure consistency with previous results and to evaluate phenotypic drift. If a significant change in PDX biology is noted, we identify the last known stable stock and re-start the model.

Drug Studies for Model: BCM-2665

Treatment Response Across All Studies

CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA

Drug Study: VFoundation

Study Metadata

Study ID: VFoundation
Study Type: Efficacy
Study Description:
Dosing Initiation Timepoint: Randomization and treatment began after average tumor size in cohort reached 150 mm³
Number of Arms: 10
Mouse Strain:

PI: Mike Lewis
Study Title: VFoundation Study
Treatments: AC, AC+C188-9, C188-9, Carbo, Carbo+C188-9, Doc20, Doc20+C188-9, Pac, Pac+C188-9
Study Duration:
Transplant Site
Transplant Material:

Study Design

Arm Type	Treatment Arms	Number of Mice
Treatment	Docetaxel20+C188-9	6
Treatment	C188-9	6
Treatment	AC	6
Treatment	Docetaxel20	6
Treatment	Carboplatin	6
Treatment	Carboplatin+C188-9	6
Control	Vehicle
Treatment	AC+C188-9	5

Treatment Results

Treatment Arm	Treatment Duration	Monitor Duration	Tumor volume over time (%)	Response Category
Docetaxel20+C188-9	28	77	102	PD
C188-9	28	77	583	PD
AC	28	77	234	PD
Docetaxel20	28	77	35	PD
Carboplatin	28	77	256	PD
Carboplatin+C188-9	28	77	419	PD
Vehicle	28	77	560	PD
AC+C188-9	28	77	196	PD

Histology Information for Model: BCM-2665

There are no histology images for this model.

Metastasis Information for Model: BCM-2665

Patient

PDX

Abdomen

Adrenal gland

Bone

Bone (de novo)

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

LMD

Liver

Lung

Lymph node

Lymph nodes

Neck

None

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

medistinal and right hilar

Patient Treatment Information for Model: BCM-2665

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response	Pathologic Response	Reason Stopped
15	Cyclophosphamide,Doxorubicin	Neoadjuvant	50.37	50.55	66 days	Progressive Disease	Not Reported	Treatment Completed
25	Docetaxel	Neoadjuvant	50.72	50.84	44 days	Not Reported	No Response	Treatment Completed
35	Radiation Therapy	Metastatic	50.85	50.9	18 days	Not Reported	Not Applicable
60	Capecitabine	Metastatic	51.0	51.08	29 days	Disease Progression	Not Applicable	Disease Progression